Apex Pharmacy Limited 15122665 true 2023-09-07 2024-09-30 2024-09-30 The principal activity of the company is that of dispensing chemist in specialised stores. Digita Accounts Production Advanced 6.30.9574.0 true Miss Shivika Babbar Mr Sanjay Babbar 15122665 2023-09-07 2024-09-30 15122665 2024-09-30 15122665 bus:OrdinaryShareClass1 2024-09-30 15122665 core:ShareCapital 2024-09-30 15122665 bus:FRS102 2023-09-07 2024-09-30 15122665 bus:AuditExempt-NoAccountantsReport 2023-09-07 2024-09-30 15122665 bus:FullAccounts 2023-09-07 2024-09-30 15122665 bus:RegisteredOffice 2023-09-07 2024-09-30 15122665 bus:Director1 2023-09-07 2024-09-30 15122665 bus:Director2 2023-09-07 2024-09-30 15122665 bus:OrdinaryShareClass1 2023-09-07 2024-09-30 15122665 bus:EntityHasNeverTraded 2023-09-07 2024-09-30 15122665 bus:PrivateLimitedCompanyLtd 2023-09-07 2024-09-30 15122665 countries:EnglandWales 2023-09-07 2024-09-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 15122665

Apex Pharmacy Limited

Annual Report and Unaudited Financial Statements

for the Period from 7 September 2023 to 30 September 2024

 

Apex Pharmacy Limited

Profit and Loss Account for the Period from 7 September 2023 to 30 September 2024

The company has not traded during the period. During this period, the company received no income and incurred no expenditure and therefore made neither profit nor loss.

 

Apex Pharmacy Limited

(Registration number: 15122665)
Balance Sheet as at 30 September 2024

Note

2024
£

Current assets

 

Cash at bank and in hand

 

100

Capital and reserves

 

Called up share capital

5

100

Shareholders' funds

 

100

For the financial period ending 30 September 2024 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.

Approved and authorised by the Board on 17 April 2025 and signed on its behalf by:
 

.........................................
Miss Shivika Babbar
Director

   
     
 

Apex Pharmacy Limited

Notes to the Unaudited Financial Statements for the Period from 7 September 2023 to 30 September 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
39 Sutton Avenue
Langley
Slough
SL3 7AP
United Kingdom

These financial statements were authorised for issue by the Board on 17 April 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The functional and presentational currency is GBP Sterling (£), being the currency of the primary economic environment in which the company operates in. The amounts are presented rounded to the nearest pound.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

Apex Pharmacy Limited

Notes to the Unaudited Financial Statements for the Period from 7 September 2023 to 30 September 2024 (continued)

2

Accounting policies (continued)

Financial instruments

Classification
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties and loans from related parties.
 Recognition and measurement
Debt instruments (other than those wholly repayable or receivable within one year), including loans and other debtors and creditors, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method.

Debt instruments that are payable or receivable within one year, typically trade creditors or debtors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration, expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms of financed at a rate of interest that is not a market rate or in case of an out-right short term loan not at a market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.

 Impairment
Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss if recognised in the Profit and loss account.

For financial assets measured as amortised cost, the impairment loss is measured as the difference between an asset’s carrying amount and the present value of estimated cash flows discounted at the asset’s original effective interest rate. If a financial asset has a variable interest rate, the discounted rate for measuring any impairment loss is the current effective interest rate determined under the contract.

Financial assets and liabilities are offset and the net amount reported in the Balance sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

3

Staff numbers

The average monthly number of persons employed by the company (including directors) during the period, was 1.

4

Cash and cash equivalents

2024
£

Cash on hand

100

 

Apex Pharmacy Limited

Notes to the Unaudited Financial Statements for the Period from 7 September 2023 to 30 September 2024 (continued)

5

Share capital

Allotted, called up and fully paid shares

2024

No.

£

Ordinary shares of £1 each

100

100

   
 

Apex Pharmacy Limited

Detailed Profit and Loss Account for the Period from 7 September 2023 to 30 September 2024

2024
£

Turnover (analysed below)

-

Operating profit/(loss)

-

Profit/(loss) before tax

-